urea has been researched along with cardiovascular agents in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 6 (26.09) | 2.80 |
| Authors | Studies |
|---|---|
| Heitz, J; Krais, T; Molzahn, M; Neumayer, HH; Schultze, G; Wagner, K | 1 |
| BARNOUD, R; CHANEL, J; CORDIER, D | 1 |
| BRAM, G | 1 |
| HARRIS, JE | 1 |
| BASTIE, J; FERNANDEZ, A | 1 |
| Fox, CJ; Kaye, AD; Liu, H; Zhang, S | 1 |
| Hosoda, S; Kasanuki, H; Kitakaze, M; Namiki, A; Sakamoto, A; Takamoto, S | 1 |
| Akaishi, M | 1 |
| Franco, OS; Irigoyen, MC; Martins, CN; Paulitsch, FS; Pereira, AP; Plentz, RD; Signori, LU; Silva, AM; Teixeira, AO | 1 |
| Hayward, LF; Hernandez, ME; Martin, EJ | 1 |
| Anatchkova, M; Chau, D; Malik, FI; Oko-Osi, H; Patrick, DL; Spertus, J; Teerlink, JR; von Maltzahn, R; Wiklund, I | 1 |
| Muretta, JM; Rohde, JA; Thomas, DD | 1 |
| Chien, FJ; Eisen, HJ; Kim, DH | 1 |
| Atigh, MK; Christians, U; Erwin, MM; Turner, EA; Yazdani, SK | 1 |
| Annoni, F; El-Oumeiri, B; Herpain, A; Jespers, P; Mc Entee, K; van de Borne, P; Van Nooten, G; Vanden Eynden, F | 1 |
| Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L | 1 |
| Agarwal, R; Chen, CS; Chopra, A; Cicconet, M; Ewoldt, J; Garfinkel, AC; Mücke, M; Neyazi, M; Pourquié, O; Rao, J; Schmid, M; Seidman, CE; Seidman, JG; Sharma, A; Toepfer, CN; Willcox, JAL | 1 |
| Lam, CSP; Teramoto, K; Tromp, J | 1 |
| Dutta, S; Lee, E; Mackowski, M; Trivedi, A; Wahlstrom, J | 1 |
| Geisler, BP; Holewijn, S; Iken, AR; Pietzsch, JB; Reijnen, MMPJ; van Wijck, IPS | 1 |
| Ingrasciotta, G; Jacoby, D; Masri, A; Morelli, C; Olivotto, I | 1 |
| Böhm, M; Cohen-Solal, A; Divanji, PH; Docherty, KF; Ezekowitz, JA; Felker, GM; Heitner, SB; Kupfer, S; Lewis, GD; Lopes, RD; Malik, FI; Meng, L; Metra, M; Teerlink, JR; Voors, AA; Whellan, DJ; Wohltman, A | 1 |
| Kok, WE | 1 |
3 review(s) available for urea and cardiovascular agents
| Article | Year |
|---|---|
Cardiovascular pharmacology: an update.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea | 2010 |
Pharmacologic Management for Heart Failure and Emerging Therapies.
Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan | 2017 |
Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond.
Topics: Cardiac Myosins; Cardiovascular Agents; Heart Failure; Humans; Sarcomeres; Urea | 2022 |
6 trial(s) available for urea and cardiovascular agents
| Article | Year |
|---|---|
The impact of eicosanoids on compliance, cardiovascular performance, and coagulation during hemodialysis.
Topics: Adult; Aged; Blood Coagulation; Blood Pressure; Cardiovascular Agents; Clinical Trials as Topic; Creatinine; Electrolytes; Epoprostenol; Heparin; Humans; Iloprost; Male; Middle Aged; Patient Compliance; Platelet Aggregation; Renal Dialysis; Urea | 1984 |
Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiovascular Agents; Diltiazem; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Urea | 2012 |
Effects of different frequencies of transcutaneous electrical nerve stimulation on venous vascular reactivity.
Topics: Acetylcholine; Adult; Analysis of Variance; Blood Glucose; Cardiovascular Agents; Cholesterol; Erythrocyte Count; Hand; Humans; Leukocyte Count; Lipoproteins, HDL; Male; Nitroprusside; Phenylephrine; Transcutaneous Electric Nerve Stimulation; Triglycerides; Urea; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Veins | 2014 |
Pharmacokinetics, Disposition, and Biotransformation of [
Topics: Administration, Intravenous; Administration, Oral; Adult; Biological Availability; Biotransformation; Cardiovascular Agents; Cytochrome P450 Family 4; Healthy Volunteers; Heart Failure; Hepatobiliary Elimination; Humans; Infusions, Intravenous; Intestinal Absorption; Male; Renal Elimination; Urea | 2021 |
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
[Positive inotropic agents for heart failure treatment: new avenues and questions].
Topics: Cardiac Myosins; Cardiotonic Agents; Cardiovascular Agents; Heart Failure; Humans; Stroke Volume; Urea | 2023 |
14 other study(ies) available for urea and cardiovascular agents
| Article | Year |
|---|---|
[Non-protein substances detected by biuret in fish blood serum; effect of corticosteroids].
Topics: Adrenal Cortex Hormones; Biuret; Blood; Cardiovascular Agents; Fishes; Pregnadienes; Proteins; Serum; Urea | 1958 |
[Clinical and double blind trials with MH 532 (Gamaquil) in tension headache].
Topics: Carbamates; Cardiovascular Agents; Double-Blind Method; Headache; Muscle Relaxants, Central; Tension-Type Headache; Tranquilizing Agents; Urea | 1962 |
CARDIOVASCULAR RENAL AGENTS AS THEY IMPINGE ON OPHTHALMIC PRACTICE.
Topics: Antihypertensive Agents; Benzothiadiazines; Bretylium Compounds; Carbonic Anhydrase Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy; Glycerol; Guanethidine; Hexamethonium Compounds; Hydralazine; Mannitol; Mecamylamine; Methyldopa; Mineralocorticoid Receptor Antagonists; Ophthalmology; Organomercury Compounds; Pargyline; Pentolinium Tartrate; Renal Agents; Reserpine; Tetraethylammonium Compounds; Toxicology; Urea; Veratrum; Veratrum Alkaloids | 1964 |
[Electroshock under phenacetylurea].
Topics: Cardiovascular Agents; Convulsive Therapy; Electroshock; Muscle Relaxants, Central; Urea | 1952 |
Intravenous infusion of ultra-short-acting β-blocker for postoperative atrial fibrillation is the one of choice.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiovascular Agents; Diltiazem; Female; Humans; Male; Morpholines; Postoperative Complications; Urea | 2012 |
Blockade of orexin receptors attenuates the cardiovascular response to air-jet stress in spontaneously hypertensive rats.
Topics: Acetamides; Air; Animals; Benzoxazoles; Blood Pressure; Brain; Brain-Derived Neurotrophic Factor; Cardiovascular Agents; Dose-Response Relationship, Drug; Heart Rate; Isoquinolines; Male; Naphthyridines; Orexin Receptor Antagonists; Orexin Receptors; Physical Stimulation; Random Allocation; Rats, Inbred SHR; Rats, Wistar; RNA, Messenger; Species Specificity; Stress, Psychological; Urea | 2016 |
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program.
Topics: Aged; Aged, 80 and over; Cardiac Myosins; Cardiovascular Agents; Clinical Trials as Topic; Dizziness; Dyspnea; Edema; Fatigue; Female; Focus Groups; Heart Failure; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Qualitative Research; Quality of Life; Sleep Initiation and Maintenance Disorders; United States; United States Food and Drug Administration; Urea | 2016 |
Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke.
Topics: Animals; Biosensing Techniques; Cardiac Myosins; Cardiovascular Agents; Cattle; Chickens; Heart Failure; Humans; Kinetics; Myocardial Contraction; Myocardium; Myosins; Phosphates; Rabbits; Urea | 2017 |
Coating and Pharmacokinetic Evaluation of Air Spray Coated Drug Coated Balloons.
Topics: Angioplasty, Balloon; Animals; Bioreactors; Cardiovascular Agents; Carotid Arteries; Coated Materials, Biocompatible; Drug Liberation; Excipients; Iohexol; Materials Testing; Paclitaxel; Serum Albumin, Bovine; Surface Properties; Sus scrofa; Tissue Culture Techniques; Tissue Distribution; Urea; Vascular Access Devices | 2018 |
Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.
Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Cardiac Myosins; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Echocardiography, Doppler; Hemodynamics; Infusions, Intravenous; Male; Rats, Wistar; Recovery of Function; Severity of Illness Index; Stroke Volume; Urea; Ventricular Function, Left | 2018 |
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Cardiovascular Agents; Diastole; Dobutamine; Drug Therapy, Combination; Heart Failure; Ivabradine; Male; Myocardial Ischemia; Swine; Treatment Outcome; Urea | 2018 |
SarcTrack.
Topics: Algorithms; Benzylamines; Cardiovascular Agents; Carrier Proteins; Clustered Regularly Interspaced Short Palindromic Repeats; Computer-Aided Design; Fluorescence; Humans; Induced Pluripotent Stem Cells; Microscopy, Atomic Force; Myocardial Contraction; Myocytes, Cardiac; Myosins; Propranolol; Sarcomeres; Software; Uracil; Urea; Verapamil; Video Recording | 2019 |
Heart failure or heart success?
Topics: Cardiovascular Agents; Evidence-Based Medicine; Ferric Compounds; Glycosides; Heart Failure, Systolic; Hospitalization; Humans; Maltose; Randomized Controlled Trials as Topic; Recovery of Function; Research Design; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left | 2021 |
Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Chronic Limb-Threatening Ischemia; Coated Materials, Biocompatible; Cost-Benefit Analysis; Excipients; Femoral Artery; Germany; Humans; Netherlands; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Urea; Vascular Patency | 2022 |